Rusfertide
Rusfertide is the first drug to control polycythaemia vera's excess red cells by restricting iron, sparing patients repeated blood removal.
VERIFY phase 3 (2025): significantly more patients phlebotomy-free versus placebo on top of standard therapy, with improved symptoms. FDA approval August 2026 for erythrocytosis in PV. Developed by Protagonist with Takeda.
- Notes
- No UK marketing authorisation as of September 2026, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
- NHS England
- Not routinely funded
Sources: NICE search: rusfertide. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Erythrocytosis in adults with polycythaemia vera |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Rusfertide" OR ABSTRACT:"Rusfertide" OR TITLE:"Mimrylo" OR ABSTRACT:"Mimrylo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rusfertide, not a curated reading list.